Clinical trial
A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the…
NCT00240929 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00240929 |
|---|---|
| Title | A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis) |
| Official title | A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis), A Humanized Respiratory Syncytial Virus Monoclonal Antibody, in Children With a History of Prematurity |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | -Unhealthy Children With a History of Prematurity |
| Intervention type | Drug |
| Interventions | MEDI-493 |
| Enrollment | 150 |
| Start date | Sep 1, 2002 |
| Completion | Apr 1, 2003 |
| First posted | Oct 18, 2005 |
| Last update posted | Nov 15, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: